, Volume 81, Issue 2, pp 289–301 | Cite as

RP-LC Method for the Determination of Seven Antiviral Drugs and Bioanalytical Application for Simultaneous Determination of Lamivudine and Penciclovir in Human Plasma

  • Sonia T. Hassib
  • Elham A. Taha
  • Ehab F. Elkady
  • Ghada H. Barakat


An RP-LC method was developed and validated for separation and determination of seven antiviral drugs in their drug substances and drug products, using a BDS Hypersil C8 column at ambient temperature. The mobile phase was composed of 0.01 M KH2PO4 (pH 4):acetonitrile in gradient mode and the quantification was achieved at 245 nm for acyclovir, ganciclovir, penciclovir and valacyclovir hydrochloride, and at 220 nm for lamivudine, oseltamivir phosphate and ribavirin. Run time was 8 min, except for the oseltamivir-containing mixture where the run time was extended to 20 min. The validation of the method was assessed according to ICH guidelines. Linearity, accuracy and precision were satisfactory over the concentration ranges 3–100 µg mL−1 for acyclovir, ganciclovir and penciclovir; 5–100, 4–100, 7–120 and 5–120 µg mL−1 for valaciclovir HCl, lamivudine, oseltamivir phosphate and ribavirin, respectively. The developed method is suitable for the quality control and routine analysis of the cited drugs separately or in combinations. Moreover, the proposed method can be used for counterfeit drug detection. Also, simultaneous determination of lamivudine and penciclovir in spiked human plasma has been developed, using valaciclovir hydrochloride as an internal standard. Protein precipitation using perchloric acid solution was used for the extraction of the drugs from plasma. With modified chromatographic conditions, quantification was achieved at 254 nm. Validation of the method was performed according to European Medicines Agency guidelines with linearity over the range 0.056–4.0 and 0.14–10.0 μg mL−1 for lamivudine and penciclovir, respectively.

Graphical abstract


Liquid chromatography Antiviral drugs Bioanalytical determination Human plasma 


Compliance with Ethical Standards

Conflict of interest

We certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
  2. 2.
    David WK, Richard JW (2007) Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University PressGoogle Scholar
  3. 3.
  4. 4.
    El-Din MKS, El-Brashy AM, Sheribah ZA, El-Gamal RM (2006) Spectrophotometric determination of acyclovir and ribavirin in their dosage forms. J AOAC-Int 89(3):631–641Google Scholar
  5. 5.
    Liang GL (2006) HPLC determination of ganciclovir and ribavirin in eye drops. Chin J Pharm Anal 26(9):1308–1310Google Scholar
  6. 6.
    Al Azzam KM, Saad B, Makahleah A, Aboul Enein HY, Elbashir AA (2010) Assay and stability indicating micellar electrokinetic chromatography method for the simultaneous determination of valacyclovir, acyclovir and their major impurity guanine in pharmaceutical formulations. Biomed Chromatogr 24(5):535–543Google Scholar
  7. 7.
    Holkar GS, Rokade MD, Yadav RR, Daphal VN (2012) Determination of assay and peak purity evaluation of acyclovir and valacyclovir by RP-HPLC method. Int J Theor Appl Sci 4(2):56–65Google Scholar
  8. 8.
    Pham Houy C, Stathoulopoulou F, Sandouk P, Scherrmenn JM, Palombo S, Girre C (1999) Rapid determination of valacyclovir and acyclovir in human biological fluids by high performance liquid chromatography using isocratic elution. J Chromatogr B Biomed Appl 732(1):47–53CrossRefGoogle Scholar
  9. 9.
    Shibata N, Kitamura A, Yoshikawa Y, Inoue T, Bamba T, Takada K (2000) Simultaneous determination of acyclovir and ganciclovir in plasma by HPLC and pharmacokinetic interactions. Pharm Pharmacol Commun 6(11):501–506CrossRefGoogle Scholar
  10. 10.
    Loregian A, Gatti R, Pal G, de Palo EF (2001) Separation methods for acyclovir and related antiviral compounds. J Chromatogr B Biomed Appl 764(1–2):289–311CrossRefGoogle Scholar
  11. 11.
    Kishino S, Takekuma Y, Sugawara M, Shimamura T, Furukawa H, Todo S, Miyazaki K (2002) Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. J Chromatogr B Anal Technol Biomed Life Sci 780(2):289–294CrossRefGoogle Scholar
  12. 12.
    Shao LH, Sun SA, Guo DM (2002) Determination of penciclovir and lamivudine concentration in human serum. Acta Acad Med Shandong.
  13. 13.
    Teshima D, Otsubo K, Yoshida T, Itoh Y, Oishi R (2003) A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high performance liquid chromatography. Biomed Chromatogr 17(8):500–503CrossRefGoogle Scholar
  14. 14.
    Dao YJ, Jiao Z, Zhong MK (2008) Simultaneous determination of acyclovir, ganciclovir and penciclovir in human plasma by high performance liquid chromatography with fluorescence detection. J Chromatogr B Anal Technol Biomed Life Sci 867(2):270–276CrossRefGoogle Scholar
  15. 15.
    Kasiari M, Gikas E, Georgakakou S, Kazanis M, Panderi I (2008) Selective and rapid liquid chromatography/negative-ion electrospray ionization mass spectrometry method for the quantification of valacyclovir and its metabolite in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 864(1–2):78–86CrossRefGoogle Scholar
  16. 16.
    Raviolo MA, Casas Breva I, Esteve Romero J (2009) Screening and monitoring antiretrovirals and antivirals in the serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography. J Chromatogr 1216(16):3546–3552CrossRefGoogle Scholar
  17. 17.
    Weller DR, Balfour HH Jr, Vezina HE (2009) Simltaneous determination of acyclovir, ganciclovir, and (R)-9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine in human plasma using high performance liquid chromatography. Biomed Chromatogr 23(8):822–827CrossRefGoogle Scholar
  18. 18.
    Kanneti R, Rajesh R, Raj JRA, Bhatt PA (2009) An LC–MS–MS method for the simultaneous quantitation of acyclovir and valacyclovir in human plasma. Chromatographia 70(3–4):407–414CrossRefGoogle Scholar
  19. 19.
    Yadav M, Upadhyay V, Singhal P, Goswami S, Shrivastav PS (2009) Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography–tandem mass spectrometry method. J Chromatogr B Anal Technol Biomed Life Sci 877(8–9):680–688CrossRefGoogle Scholar
  20. 20.
    Shi CB, Bai XH, Jiang LF, Wu SM (2006) Simultaneous and rapid determination of acyclovir, ganciclovir and penciclovir in plasma with solid phase extraction and HPLC. Chin J Pharm Anal 26(9):1199–1203Google Scholar
  21. 21.
    Kromdijk W, Pereira SA, Rosing H, Mulder JW, Beijnen JH, Huitema A (2013) Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography–tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 919–920(1):43–51CrossRefGoogle Scholar
  22. 22.
    El Din MS, Eid M, Talaat W (2013) Micellar liquid chromatographic determination of ribavirin, silybin, interferon[alpha]-2a, lamivudine and ursodeoxycholic acid in dosage forms and biological fluids. J Liq Chromatogr Relat Technol 37(13):1785–1804CrossRefGoogle Scholar
  23. 23.
    Guideline for the development of measures to combat counterfeit drugs (1999) Department of Essential Drugs and Other Medicines. World Health Organization, GenevaGoogle Scholar
  24. 24.
    Colledge D, Locarnini S, Shaw T (1997) Hepatology 26:216–225 (copyright © 1997 by the American Association for the study of liver diseases) Google Scholar
  25. 25.
    Lamivudine PK Fact Sheet (March 2016) University of Liverpool, produced by Accessed Nov 2016
  26. 26.
    The comprehensive resource for physicians, drug and illness information, Famvir™. Accessed June 2016
  27. 27.
  28. 28.
    United States Pharmacopoeia (40) The national formulary 35 (2017)Google Scholar
  29. 29.
    (1996) Q 2(R 1) validation of analytical procedures: text and methodology. In: Proceedings of the international conference on harmonisation (ICH). Commission of the European Communities, Geneva (incorporated in 2005) Google Scholar
  30. 30.
    European Medicines Agency (2014) Guidline on bioanalytical method validation. Committee for Medicinal Products for Human Use (CHMP), LondonGoogle Scholar
  31. 31.
    Guidance for industry, bioanalytical method validation (2013) U.S. Department of Health and Human Services, Food and Drug Administration, RockvilleGoogle Scholar
  32. 32.
    British Pharmacopoeia (2016) The Stationary Office, LondonGoogle Scholar
  33. 33.
    Surendra babu K, Uma maheswarasarma K, Sai Phani Kumar KASVR, Phani RSCH (2011) New RP-HPLC method development and validation for analysis of antiviral drug penciclovir. Int J Res Pharm Chem 1(1):33–35Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • Sonia T. Hassib
    • 1
  • Elham A. Taha
    • 2
  • Ehab F. Elkady
    • 1
  • Ghada H. Barakat
    • 2
  1. 1.Pharmaceutical Chemistry Department, Faculty of PharmacyCairo UniversityCairoEgypt
  2. 2.National Organization for Drug Control and Research (NODCAR)GizaEgypt

Personalised recommendations